YIH
TVTX icon

Y-Intercept (HK)’s Travere Therapeutics TVTX Stock Holding History

Y-Intercept (HK)’s Portfolio TVTX Stock Details TVTX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		– Sell
-117,361
Closed -$3.49M – 2176
2026
Q1 		$3.49M Buy
117,361
+77,793
+197% +$2.33M 0.07% 472
2025
Q4 		$1.51M Sell
39,568
-54,757
-58% -$1.78M 0.03% 764
2025
Q3 		$2.25M Buy
94,325
+26,325
+39% +$495K 0.05% 545
2025
Q2 		$1.01M Buy
68,000
+52,675
+344% +$873K 0.02% 937
2025
Q1 		$275K Buy
+15,325
New +$311K 0.02% 933
2024
Q4 		– Sell
-28,217
Closed -$395K – 1668
2024
Q3 		$395K Sell
28,217
-67,065
-70% -$699K 0.02% 893
2024
Q2 		$783K Buy
95,282
+77,474
+435% +$522K 0.04% 607
2024
Q1 		$137K Buy
+17,808
New +$150K 0.01% 1225

Other funds holding TVTX

Assenagon Asset Management
Assenagon Asset Management Senningerberg, Luxembourg $80.2B AUM 50.57% 1-Year Est. Return
HWAM
Hennion & Walsh Asset Management Parsippany, New Jersey $3.5B AUM 41.95% 1-Year Est. Return
ORI
Oak Ridge Investments Chicago, Illinois $1.77B AUM 63.16% 1-Year Est. Return
BC
Burney Company Reston, Virginia $3.71B AUM 37.66% 1-Year Est. Return
Handelsbanken Fonder
Handelsbanken Fonder Stockholm, Sweden $35.1B AUM 47.76% 1-Year Est. Return
DT
Diversified Trust Memphis, Tennessee $6.24B AUM 28.78% 1-Year Est. Return
HCMT
Highland Capital Management (Tennessee) Memphis, Tennessee $2.17B AUM 54.74% 1-Year Est. Return
Wealth Enhancement Advisory Services
Wealth Enhancement Advisory Services Plymouth, Minnesota $59.8B AUM 29.42% 1-Year Est. Return
Mirae Asset Global Investments
Mirae Asset Global Investments Seoul, South Korea $67.7B AUM 51.91% 1-Year Est. Return
NS
NBC Securities Birmingham, Alabama $1.48B AUM 31.07% 1-Year Est. Return

Y-Intercept (HK)'s TVTX Position: Q2 2026 in Review

Y-Intercept (HK) sold out of Travere Therapeutics (TVTX) in Q2 2026, closing a stake of 117,361 shares — an estimated $3.49M sold.

Y-Intercept (HK) first reported a position in TVTX in Q1 2024 and held it in 8 quarters. The position peaked at $3.49M in Q1 2026. 26 funds tracked by Wall St. Rank hold TVTX as of Q2 2026.

  • Y-Intercept (HK) reported no remaining Travere Therapeutics position as of Q2 2026 after selling out during the quarter.
  • Y-Intercept (HK) sold 117,361 Travere Therapeutics shares in Q2 2026, an estimated $3.49M.
  • Y-Intercept (HK) first reported a position in Travere Therapeutics in Q1 2024 and held it in 8 quarters.
  • Y-Intercept (HK)'s Travere Therapeutics position peaked at $3.49M in Q1 2026.
  • 26 funds tracked by Wall St. Rank held Travere Therapeutics as of Q2 2026.

Based on Y-Intercept (HK)'s 13F filing for Q2 2026, filed 14 Jul 2026.